(25.03.2019, 17:02)bimbes schrieb:(24.03.2019, 13:22)bimbes schrieb:(23.03.2019, 13:42)Ventura schrieb: Biogen
A common measure of a stock’s relative value is the multiple of its price to estimated earnings per share. At its current price of $226 a share, Biogen is trading at a multiple of about eight times earnings. It will take a decline of about 10 percent to put Biogen in the bargain bin.
“Everyone is trying to understand where the floor is,” said Suneja, the Guggenheim analyst.
That could take a while. Like I said, not for the faint of heart.
https://www.bostonglobe.com/business/201...story.html
in einem MOnat Wissen wir mehr
http://investors.biogen.com/news-release...il-24-2019
es wird auch ohne Alzheimer Disease weiter gehen
http://investors.biogen.com/static-files...e770386d6e
weiter geht es:
Biogen kündigt 5 billion USD Aktienrückkauf an, zusätzlich zu dem bestehendem Programm aus 2018 (mit 1,7 bill)
https://www.sec.gov/Archives/edgar/data/...chases.htm
you made my day!
Meine Pos ist etwas zu groß...